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Objective – To assess the hemodynamic profile of
cardiac surgery patients with circulatory instability in the
early postoperative period (POP).
Methods – Over a two-year period, 306 patients un-
derwent cardiac surgery.  Thirty had hemodynamic
instability in the early POP and were monitored with the
Swan-Ganz catheter. The following parameters were
evaluated: cardiac index (CI), systemic and pulmonary
vascular resistance, pulmonary shunt, central venous
pressure (CVP), pulmonary capillary wedge pressure
(PCWP), oxygen delivery and consumption, use of vaso-
active drugs and of circulatory support.
Results – Twenty patients had low cardiac index
(CI), and 10 had normal or high CI. Systemic vascular
resistance was decreased in 11 patients. There was no
correlation between oxygen delivery (DO
2
) and consump-
tion (VO
2
), p=0.42, and no correlation between CVP and
PCWP, p=0.065. Pulmonary vascular resistance was
decreased in 15 patients and the pulmonary shunt was
increased in 19. Two patients with CI < 2L/min/m2 recei-
ved circulatory support.
Conclusion – Patients in the POP of cardiac surgery
frequently have a mixed shock due to the systemic inflam-
matory response syndrome (SIRS). Therefore, invasive
hemodynamic monitoring is useful in handling blood volu-
me, choice of vasoactive drugs, and indication for circula-
tory support.
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In 1945, Leniz Dexter performed the first catheterization
of the pulmonary artery to diagnose congenital heart dise-
ase 1. The history of the clinical hemodynamic monitoring
began after the publication by Swan and Ganz introducing
the use of the balloon catheter for the pulmonary artery, in
1970 2. The use of the Swan-Ganz catheter (SGC) has
increased each year throughout the world, despite being an
invasive and expensive procedure 3. In 1975, it was emplo-
yed in 7.2% of the patients with acute myocardial infarction
(AMI), increasing to 19.9% in 1984 4.
Since the report by Gore et al 4 on the use of the SGC in
patients with AMI, where a higher mortality was shown in
patients monitored with the SGC as compared with those
monitored with the central venous catheter (CVC), there
has been great controversy in the literature about the costs
and benefits of that type of monitoring 5-8.
The dispute culminated with the publication of an edi-
torial by Dalen and Bone3 asking for the suspension of the
monitoring with the SGC until randomized and comparative
studies could be performed to better define the risks.
The objective of our study was to analyze, retros-
pectively, the hemodynamic profile of patients undergo-ing
cardiac surgery with circulatory instability in the early
postoperative period (POP), discuss our experience and the
benefits obtained with the SGC in this category of patients.
Methods
A retrospective study was performed. We analyzed
the medical records of all patients who underwent cardiac
surgery and were admitted to the intensive care unit of the
HC-UNICAMP, in the years of 1995 and 1996, and who
required hemodynamic monitoring with the SGC due to he-
modynamic instability in the early POP.
In all patients with instability following cardiac sur-
gery, the first drug used for hemodynamic support was
dopamine. Those patients who remained hypotensive
(systolic pressure <90mmHg) with 10µg/kg/min of dopa-
mine underwent invasive hemodynamic monitoring with
the SGC. The need for a second drug (dobutamine, nora-
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drenaline or sodium nitroprusside) or circulatory support
was determined only after invasive monitoring.
The following parameters were assessed: cardiac index
(CI), pulmonary (PVR) and systemic vascular resistance (SVR),
pulmonary shunt, oxygen delivery and consumption, and
correlation between central venous pressure (CVP) and
pulmonary capillary wedge pressure (PCWP). The use of
vasoactive drugs and their indications due to the measurements
obtained through monitoring were also evaluated, as was the
use of circulatory support in patients with CI <2L/min/m2.
The Pearson correlation coefficient was used for the
statistical analysis, with a level of significance of 5% (p<0.05).
Results
During 1995 and 1996, 306 patients in the POP of cardiac
surgery were admitted to the intensive care unit of the HC-
UNICAMP.
Thirty of these patients, with a mean age of 57.72±14.37
years, were monitored with the SGC due to hemodynamic
instability in the early POP. Twenty-one of these patients were
males. Their types of surgery are listed in table I.
The following hemodynamic measures were obtained: CI –
20 patients had CI <3.5L/min/m2; 7 patients had CI >4.1L/min/m2;
and 3 patients had values of CI within the acceptable range (3.5-4
L/min/m2). The minimal value found was 1.35L/min/m2, the maximal
was 6.84L/min/m2 and the mean was 3.14±1.36L/min/m2 (fig. 1).
Ten patients had a normal systemic vascular resis-
tance (SVR); 11 patients had SVR <800 dyn/sec/cm5 and 9
patients had SVR >1201 dyn/sec/cm5. The minimal value was
312 and the maximal value was 2425 dyn/sec/cm5 (fig. 2).
In 11 patients, the PVR was normal; in 15 patients, PVR
was <150 dyn/sec/cm5 and in 4 patients, PVR was >250 dyn/
sec/cm5 (fig. 3).
Table  I - Diagnosis of patients monitored with the Swan-Ganz
catheter
Mitral replacement 6
Second mitral replacent 1
Mitral valvoplasty 1
Mitral replacement + revascularization 1
Mitral replacement + tricuspid plasty 1
Aortic replacent 1
Aortic replacement + revascularization 1
Secondaortic replacement + revascularization 1
Second aortic-mitral replacement 1
Aortic-mitral replacement + revascularization 1
Aortic dissection 1
Myocardial revascularization 14
Total 30
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Fig. 1 – Cardiac index CI L/min/m2. Mean value 3.14 ± 1.36; min 1.35; max 6.84.
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Fig. 4 – Pulmonary shunt. Pulmonary shunt %.
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Fig. 3 – Pulmonary vascular resistency. PVR- dyn/s/cm5.
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Fig. 2 – Systemic vascular resistency. SVR- dyn/s/cm5.
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One patient had an acceptable pulmonary shunt (up
to 5%); in 5 patients it ranged from 6 to 10%; in 11 patients
from 11 to 20%; in 8 patients from 21 to 30%; in 2 patients
from 31 to 40%; and in 1 patient >40% (fig. 4).
The mean value for DO
2
 was 656.07±231.9mL/min/m2
and for VO
2
 was 282.52±139.43mL/min/m2. There was no
correlation between DO
2
 and VO
2
 (p=0.42) (fig. 5). There was
also no correlation between CVP and PCWP (p=0.065) (fig. 6).
The vasoactive drugs used according to data ob-
tained during monitoring are listed in table II.
Dobutamine was used in one patient; dopamine in 4;
association of dobutamine and dopamine in 10 patients; as-
sociation of dobutamine, dopamine and norepinephrine in 9
patients; association of dopamine and norepinephrine in 4;
association of dobutamine, dopamine and sodium nitro-
prusside in 2; and association of dobutamine and sodium ni-
troprusside in one patient.
Five patients had CI <2L/min/m2 and required circu-
latory support. Table III shows the values for CI and SVR,
drugs used, type of circulatory support and outcome of
each patient. Mechanical circulatory support was used in
only 2 patients.
One patient had significant bleeding, another had
Leriche’s syndrome, and another patient improved after
using vasoactive drugs. In these cases, therefore, circula-
tory support was not employed.
There were no complications deriving from the use of
the SGC.
Among the monitored patients, 16 died and 14 had a
good outcome.
All patients without initial hemodynamic stability,
who did not use the SGC, did not die. In the whole group, the
mortality rate was 5.25%. Of all patients with hemodynamic
instability monitored with the SGC, 3 had preoperative
ejection fraction (EF) <40% and 2 died; from the 7 patients
with EF between 40% and 55%, 5 died; from the 20 patients
with EF >55%, 9 died. Among the 16 patients who died, 2
had coronary heart disease in 2 arteries, 5 patients in 3 arte-
ries, and 3 patients had coronary heart disease asso-ciated
with valvular heart disease. From the patients with valvular
heart disease who died, 4 had single-valve disease and one
patient had a double-valve disease. One patient with cardio-
myoplasty evolved with severe systemic inflammatory
response syndrome (SIRS) in the POP and died. Seven pati-
ents who died had chronic obstructive pulmonary disease,
4 had diabetes mellitus and 2 had chronic renal failure.
Discussion
Invasive hemodynamic monitoring with the SGC has a
broad use in situations of hemodynamic instability in
critically ill patients.
 Table  II - Vasoactive drugs used
Number of  patients
Dobutamine 1
Dopamine 4
Dopamine + dobutamine 10
Dopamine + dobutamine + noradrenaline 9
Dopamine + noradrenaline 4
Dobutamine + dopamine + nitroprusside 2
Dobutamine + nitropusside 1
Total 30
Table  III - Patients with cardiac index < 2.0 L/min/m2
CI/SVR Circulatory support Drugs Outcome
1 1.9/1369 IAB Db, D, SN -
2 1.6/1134 Bleeding Db, D -
3 1.6/1653 IAB + CP Db, D, SN +
4 1.8/1140 Leriche's Db, D -
Syndrome
5 1,35/2425 - Db, SN +
CI/SVR- cardiac index / systemic vascular resistance; Db- dobutamine; D-
dopamine; SN- sodium nitroprusside; +: good outcome; -: death; IAB:
intraaortic balloon; CP: centrifuge pump.
Fig. 5 – Correlation between DO
2
 and VO
2
 (ml/min). There was no significant
correlation between DO
2
 and VO
2
 (p = 0.42).
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Fig. 6 – Correlation between central venous pressure (CVP) and pulmonary
capillary wedge pressure (PCWP). There was no significant correlation between
PVC and PCWP (p = 0.065).
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In the United States, around 1 million catheters are
used per year for hemodynamic monitoring at a cost of 2 bi-
llion dollars 3.
Gore et al 4, in a study published in 1987 on the use of
SGC in patients with complicated AMI, observed a higher
mortality in the group monitored with the SGC as compared
with the group monitored with the CVC. That study was
neither prospective nor randomized, allowing us to assume
that the patients monitored with the SGC were in a more cri-
tical condition. After that study, many others were publi-
shed in the search for the answer to the question: is it worth
spending so much money on a monitoring procedure that
does not increase the patient’s survival? 5-8
We retrospectively evaluated 30 patients who had
undergone cardiac surgery. These patients had hemody-
namic instability in the early POP and underwent invasive
hemodynamic monitoring with SGC. Our study showed
that in the POP of cardiac surgery, most of the patients had
hemodynamic instability resulting from mixed or hyperdy-
namic shock due to SIRS.
Measurements obtained by hemodynamic monitoring
defined our therapeutical management and, in 13 patients,
norepinephrine was used to enhance the vascular tonus.
Sodium nitroprusside was used in only 3 patients (table II).
Another point to be stressed is that we did not find
the correlation between CVP and PCWP. It is known that
the control of the blood volume based only in the measu-
rement of CVP is not safe.
Hemodynamic monitoring also guided us in the
indication for mechanical circulatory support in patients
with CI <2L/min/m2. Circulatory support with the centrifuge
pump associated with the intraaortic balloon was used in
one patient and, in another patient, only the intraaortic ba-
lloon was used.
Davies et al9 also concluded that monitoring with the
SGC was useful for orienting the control of the blood volu-
me, the use of vasoactive drugs and even the choice of the
anesthesia employed in 220 surgical patients.
We found no correlation between DO
2
 and VO
2
, as pre-
viously observed by Routse et al 10.
As the hemodynamic monitoring with the SGC is a
very invasive and expensive method, less invasive and ex-
pensive methods are currently being investigated.
Transesophageal Doppler echocardiography might
be a solution to this problem; however, the values obtained
with this method vary greatly when compared with those
obtained with the SGC 11.
Thoracic bioimpedance has similar limitations. Thomas
et al 12 compared cardiac output (CO) measurement with
bioimpedance and SGC in 28 patients after myocardial revas-
cularization. In intubated patients, bioimpedance showed up
to 30% smaller values than those obtained with the SGC.
Monitoring with the SGC has its risks and complications. In
our study, however, the patients monitored with the SGC
showed no complications related to the use of the catheter.
Nishikawa et al 13 divided the complications into two
groups: those caused by the venous puncture and those
due to the SGC. Pneumothorax had an incidence of 1% to
6% and arrhythmias of 30% to 60%. In the 1970s, pulmonary
infar-ction had an incidence of up to 7.2%; after the use of
intra-flow, however, the risk was practically abolished.
The incidence of thrombosis inside the cardiac cham-
bers, where the catheter passes, was 30%, in the postmor-
tem studies. Rupture of the pulmonary artery occurred in
0.1% to 0.2% and sepsis in 1% of the patients.
During the measurement of the CO, several errors can
occur due to temperature, injected volume, time of in-
jection, administration of fluids, hypotension, slow flow,
incorrectly positioned catheter, shunts and other problems.
Wallace et al 14 found great differences in the values of
CO measured with the use of saline solution at room tempe-
rature, when compared with the values obtained using a
cold saline solution.
In 1989, Tuman et al 15 assessed morbidity and morta-
lity in 1,094 patients with complicated AMI, comparing
monitoring with CVC and SGC and found no difference.
Zion et al 16 compared both modalities of monitoring in 371
patients and observed a higher mortality in patients with se-
vere ventricular failure monitored with SGC. Out of our 30
patients monitored with the SGC, 16 died and 14 survived.
From the patients who died, 9 had a normal EF in the
preoperative period. They developed hemodynamic
instability due to SIRS or mixed shock, which led to multior-
gan failure and death. Patients with triple coronary heart di-
sease or association of coronary heart disease with valvular
heart disease were at a higher risk. With regard to previous
diseases, chronic obstructive pulmonary disease (COPD)
had the highest risk and almost half of the patients (7) who
died, had COPD associated with cardiac disease.
Pearson et al 8 evaluated the cost/benefit ratio of three
modalities of monitoring after cardiac surgery, in 226
patients: CVC, SGC, and SGC plus continuous venous sa-
turation. This randomized study showed a much higher
cost in patients monitored with the SGC, with no differences
in mortality; however, patients monitored with CVC and with
higher instability were randomized again for the two other
modalities of monitoring. At the end of the research, only 28
patients out of 226 were monitored with the CVC.
In the review by Matthay et al 5, the success rate of the
values of the PCWP and CO, through the clinical evaluation
of intensive care unit patients, did not reach 50%. This con-
firmed our opinion that in cases of cardiac surgery with he-
modynamic instability, it is impossible to manage the
patient without invasive monitoring, which defines the type
of  hemodynamic alteration and the appropriate vasoactive
drugs to be used.
The Ontario group organized a prospective and ran-
domized study 17 comparing monitoring with the SGC and
CVC, but they could only gather 33 patients, because the
physicians refused to leave the critically ill patients without
invasive monitoring due to ethical reasons. Guyatt et al 17
published the results obtained in these 33 patients showing
the same mortality with the two modalities of monitoring.
Discussion about the use of the SGC called so much
138
Dragosavac e cols.
Postoperative hemodynamic monitoring
Arq Bras Cardiol
volume 73, (nº 2), 1999
 1. Dexter BL, Haynes FW, Burwel CS, Eppinger EC, Seibel RE, Evans JM. Studies
of congenital heart disease I: Technique of venous cateterization as a diagnostic
procedure. J Clin Invest 1947; 26: 547-53.
2. Swan HJC, Ganz W, Forrester J, Marcus H, Diamond G, Chonete D. Catheterisati-
on of the heart in man with use of the a flow-directed bolloon-tipped catheter. N
Engl J Med 1970; 283: 447-51.
3. Dalen JE, Bone RC. Is it time to pull the pulmonary artery  catheter? JAMA, 1996;
18: 916-18.
4. Gore JM, Goldberg RJ, Spodick DH, Alpert JS, Dalen JE. A community wide as-
sessment of the use of pulmonary artery catheters in pacients with acute myocardi-
al infarction. Chest 1987; 92: 721-7.
5. Matthay MA, Chatterjeek K. Bedside catheterisation on of the pulmonary artery:
Risks compared with benefits. Ann Int Med 1988; 109: 826-34.
6. Cernaianu AC, Moore MW, Posner MA. Invasive monitoring of cardiac surgical
patient. Anesth Analg 1990; 70: 671-3.
7. Chung RS, Magilligan D, Eisiminger RR, Fried MA, Serwatowski JA, Gerdeman
KS. Prediction of post-cardiopulmonary bypass   cardiac output. Ann Thorac
Surg 1989; 47: 297-9.
8. Pearson KS, Gomez MN, Moyers JR, Carter JG, Tinker JH. A cost/benefit analisis
of randomized invasive monitoring patients undergoing cardiac surgery. Anesth
Analg 1989; 69: 336-41.
9. Davies MJ, Cronin HD, Domaingue CM. Pulmonary artery catheterization. An as-
sessment of risks and benefits in 220 surgical patients. Anaesth Intensive Care
1982; 10: 9-14.
10. Routsi C, Vincent JL, Bakker J, et al. Relation between oxygen consumption and
oxigen delivery in patients after cardiac surgery. Anesth Analg 1993; 77: 1104-10.
11. Jardin F, Valtier R, Beauchet A, Dubourg O, Bourdarias JP. Invasive monitoring
combined with two-dimensional echocardiographic study in septic sho-
ck.Intensive Care Med 1994; 20: 550-4.
12. Thomas NA, Ryan J, Doran BRH, Polard BJ. Bioimpendance versus thermodilu-
tion cardiac output measurement: the Bomed NCCOM3 after coronary bypass
surgery. Intensive Care Med 1991; 17: 383-6.
13. Nishikawa T, Dohi S. Errors in the measurement of cardiac output by ther–modi-
lution. Can J Anaesth 1993; 40: 142-53.
14. Wallace DC, Winslow EH. Measurement of cardiac output.Effects of iced and ro-
om temperature injectate on cardiac output measurements in critically ill patients
with low and high cardiac outputs.Heart Lung 1993; 22: 55-63.
15. Tuman K J, Mc Carthy RJ, Spiess BD, et al. Effect of pulmonary artey catheterisati-
on on autcome in patients undergoing coronary artery surgery.Anesthesiology
1989; 70: 199-206.
16. Zion MM, Balkin J, Rosenmann D, SPRINT study group. Use of pulmonary artery
catheters in patients with acute myocardial infarction. Analysis of experience in
5841 patients in the SPRINT registry. Chest 1990; 98: 1331-5.
17. Guyatt G and Ontario Intensive Care Study Group. A randomized control trial of the
right heart catheterisation in criticaly ill pacients. J Intensive Care Med 1991; 6 : 91-5.
18. Robin E. Defenders of the pulmonary artery catheter. Chest 1988; 93: 1059-66.
19. Pulmonary Artery Catheter Conferance Participants. Pulmonary artery catheter
consensus conference:consensus statement. Crit Care Med 1997; 25: 910-24.
20. Sibbald WJ, Sprung CL. The pulmonary artery catheter. The debate continues.
Chest 1988; 94: 899-901.
21. Shak K, Sami H, Rao TLK. Cost of invasive monitoring; A yet unresolved issue.
Anesth Analg 1990; 70: 463-4.
 References
attention to the intensivists, that the journal Chest publi-
shed a series of letters with the title: “Defenders of the pul-
monary artery catheter” 18.
The consensus statement about the use of the SGC in
cardiac surgery published by the journal Critical Care
Medicine, in 1997 19, defined that invasive hemodynamic
monitoring with SGC could be useful in patients undergoing
high-risk car-diac surgery, with impairment in ventricular
function, con-cluding that there were no scientific bases to
justify the temporary suspension of the use of the SGC. The
discus-sion, however, continues 20,21.
We conclude that hemodynamic monitoring with the
SGC is fundamental in patients undergoing cardiac surgery,
who have hemodynamic instability in the POP. The value of
PCWP is important to assess the blood volume of the pa-
tient; measurement of SVR is fundamental for the choice of
vasoactive drugs, and the CI is fundamental in the indica-
tion for circulatory support.
